Abstract
Objectives:
To compare the single effect of administering ePROs to patients with cancer versus a control condition.
Methods:
Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Randomised controlled trials evaluating ePRO interventions, improving health-related outcomes, among cancer patients were included. Primary outcome:
health-related quality of life (HRQOL). Secondary outcomes: symptoms, hospital
admissions, unplanned visits, chemotherapy completion, survival, and satisfaction with care. Effect size of ePROs on health-related outcomes were analysed as standardised mean differences with 95% confidence intervals using the random effects model.
Results:
The search identified 10965 papers. Nineteen papers from 15 studies were included.Meta-analysis showed an improvement in HRQOL at three months, measured by the Functional Assessment of Cancer Therapy- General (FACT-G) (SMD: 0.28 95% CI: -1.22 to 1.78), and at six months with various HRQOL measures (SMD: 0.07 95% CI: -1.24 to 1.39). Results should be interpreted with caution given the wide confidence intervals. Nine studies reported a positive signal on HRQOL with six including tailored patient
advice and six using clinician alert systems.
To compare the single effect of administering ePROs to patients with cancer versus a control condition.
Methods:
Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Randomised controlled trials evaluating ePRO interventions, improving health-related outcomes, among cancer patients were included. Primary outcome:
health-related quality of life (HRQOL). Secondary outcomes: symptoms, hospital
admissions, unplanned visits, chemotherapy completion, survival, and satisfaction with care. Effect size of ePROs on health-related outcomes were analysed as standardised mean differences with 95% confidence intervals using the random effects model.
Results:
The search identified 10965 papers. Nineteen papers from 15 studies were included.Meta-analysis showed an improvement in HRQOL at three months, measured by the Functional Assessment of Cancer Therapy- General (FACT-G) (SMD: 0.28 95% CI: -1.22 to 1.78), and at six months with various HRQOL measures (SMD: 0.07 95% CI: -1.24 to 1.39). Results should be interpreted with caution given the wide confidence intervals. Nine studies reported a positive signal on HRQOL with six including tailored patient
advice and six using clinician alert systems.
| Original language | English |
|---|---|
| Journal | JOURNAL OF MEDICAL INTERNET RESEARCH |
| DOIs | |
| Publication status | Accepted/In press - 10 Apr 2024 |